Leap Therapeutics Inc (STU:5MC)
€ 2.62 -0.1 (-3.68%) Market Cap: 101.82 Mil Enterprise Value: 42.34 Mil PE Ratio: 0 PB Ratio: 2.27 GF Score: 35/100

Leap Therapeutics Inc ASCO GI 2022 DisTinGuish Study Conference Call Transcript

Jan 21, 2022 / 06:00PM GMT
Release Date Price: €19.7 (-21.51%)
Operator

Good day, everyone, and welcome to the Leap Therapeutics DKN-01 Clinical Investigator Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

At this time, I will now turn the call over to Dr. Cynthia Sirard, Chief Medical Officer of Leap. Please begin.

Cynthia A. Sirard
Leap Therapeutics, Inc. - Chief Medical Officer

Thank you, operator. Welcome, and thank you to those of you joining us today for an update on Leap Therapeutics DKN-01 development program. I'm Cynthia Sirard, and with me today are Dr. Samuel Klempner, an Associate Professor at Harvard Medical School, who leads the gastric and esophageal cancer program at Massachusetts General Hospital Cancer Center; J. Baum, Vice President and Head of Translational Medicine at Leap; and Douglas Onsi, President and Chief Executive Officer at Leap.

This call is being accompanied by a slide deck, so I will ask you to please turn to our forward-looking statements on Slide 2. I would like to remind you that any statements made during

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot